Source: Virtual Congress 2020 – Translational therapeutic advances
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Jahn (Palma De Mallorca, Spain), C. Rio (Palma De Mallorca, Spain), A. Martin-Medina (Palma De Mallorca, Spain), A. Igleasias Coma (Palma De Mallorca, Spain), J. Mercader Barceló (Palma De Mallorca, Spain), O. Gigirey (Palma De Mallorca, Spain), C. Villena (Palma De Mallorca, Spain), E. Sala Linas (Palma De Mallorca, Spain). Intratracheal application of healthy lung derived Mesenchymal Stem Cells (DON-MSC) in the form of biospheres (BS) as potential therapeutic agents for chronic lung disease. 3349

Member's Comments

No comment yet.

Related content which might interest you: Pluripotent stem cells isolated from adult human lung tissue exhibit anti-fibrotic properties Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013 Differentiation of Induced Pluripotent Stem Cells (iPSC) into human bronchial epithelium from healthy and severe COPD patients. Source: International Congress 2018 – A fresh view on airway differentiation and regeneration Year: 2018 Mesenchymal stem cell therapy in a model of chronic inflammatory lung disease Source: International Congress 2019 – Cellular responses and cell therapy in lung injury and repair Year: 2019 Oral presentation: Human lung parenchyma cells: a potential therapeutic cell source for lung disease Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis Year: 2009 Late Breaking Abstract - Enhancing the antimicrobial efficacy of mesenchymal stem cells (MSCs) to combat sepsis-induced acute lung injury (ALI) using a novel combination of immune-stimulants Source: International Congress 2017 – Late-breaking findings in pulmonary diseases Year: 2017 Effects of autologous mesenchymal stromal cell treatment for severe emphysema on lung tissue: A clinical trial Source: International Congress 2015 – The multiple facets of stem and progenitor cells in lung health and disease Year: 2015 Effect of low level laser (LLL) and mesenchymal stem cells (htMSCs) therapies on cigarette-induced lung inflammation in mice Source: Annual Congress 2013 –Tobacco use in different countries: crisis to disease Year: 2013 Synergistic effect of human tubal mesenchymal stem cell (htMSCs) and low level laser (LLL) therapy significantly reduces experimental COPD in mice Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Both intranasal and intraperitoneal administration of human tubal mesenchymal stem cells (htMSC) ameliorates experimental COPD model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Mesenchymal stem cell therapy reduces inflammation and damage in a model of chronic lung disease Source: ERS Lung Science Conference 2017 Year: 2017 Pulmonary alveolar proteinosis: iPS derived macrophages as in-vitro disease model and potential source for novel gene and cell therapies Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Mesenchymal stem cells and fibrotic lung diseases Source: International Congress 2014 – Targeting lung fibrosis: from bench to bedside Year: 2014 Efficacy of functionalized-imatinib loaded gold nanoparticles on lung fibroblastoid cells from systemic sclerosis patients Source: International Congress 2016 – Connective tissue disorders Year: 2016 Immunomodulatory properties of Lung Resident Mesenchymal Stem Cells in patients with COPD Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018 Identification and characterization of mesenchymal stem cells in the human lung Source: International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema Year: 2015 Comparative effects of inhaled and intravenous mesenchymal stem cells in bleomycin-induced pulmonary fibrosis in rabbits Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013 Functional comparison of bone-marrow derived mesenchymal stromal cells obtained from COPD patients and non-COPD controls Source: International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema Year: 2015 Prospective phase 1 open clinical trial to study the safety of adipose derived mesenchymal stem cells (ADMSCs) in COPD and combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015 Stem cells and lung cancer treatment: any hope? Source: International Congress 2016 – Molecular footprints in lung cancer diagnosis and management Year: 2016